KBI Biopharma

Absci is a drug and target discovery company that utilizes deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. By employing its Integrated Drug Creation Platform, Absci identifies novel drug targets and discovers optimal biotherapeutic candidates while simultaneously generating the necessary cell lines for manufacturing. This innovative approach allows biotech and pharmaceutical partners to develop next-generation protein-based drugs, including Bionic Proteins that incorporate nonstandard amino acids and other unique drug designs that may be unattainable through traditional methods. Absci's mission focuses on advancing the development of improved medicines by effectively translating innovative ideas into viable drugs.

Absci is a drug and target discovery company that utilizes deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. By employing its Integrated Drug Creation Platform, Absci identifies novel drug targets and discovers optimal biotherapeutic candidates while simultaneously generating the necessary cell lines for manufacturing. This innovative approach allows biotech and pharmaceutical partners to develop next-generation protein-based drugs, including Bionic Proteins that incorporate nonstandard amino acids and other unique drug designs that may be unattainable through traditional methods. Absci's mission focuses on advancing the development of improved medicines by effectively translating innovative ideas into viable drugs.

Comera Life Sciences is a pre-clinical biotechnology company focused on transforming biologic medicines from intravenous to subcutaneous forms. The company utilizes its proprietary SQore platform, which includes patented, FDA-friendly excipients, to enhance the formulation of therapeutic biologics. This technology aims to make life-saving medicines easier to administer, reduce immunogenicity, increase stability, and improve production efficiency. Comera collaborates with pharmaceutical and biotechnology companies, applying its innovative techniques to optimize existing subcutaneous biologics and develop biosimilar versions of current products. Through these efforts, Comera Life Sciences seeks to improve treatment options for fragile patients and advance the field of formulation science.

Elion Labs is a contract services organization dedicated to meeting the analytical development and product characterization needs of the biopharmaceutical industry. The company provides a range of services, including analytical method development, qualification and validation, and analytical characterization testing of biologics. Additionally, Elion offers formulation development, specialized training in analytical techniques, and comprehensive data analysis that includes the visualization and interpretation of complex data sets. The organization also focuses on technical and regulatory writing and consulting. Elion Labs is committed to delivering its services with a high level of professionalism, quality, and efficiency.

GlycoSeLect is a biotechnology company focused on developing and producing Recombinant Prokaryotic Lectins (RPLs), which are innovative tools for analyzing and selectively purifying glycosylated biomolecules. Their RPLs have diverse applications in life sciences, including glycobiology, glycoproteomics, biomarker discovery, biomedical diagnostics, and the biopharmaceutical industry, as well as in vaccines and cosmetics. GlycoSeLect's RPLs offer notable advantages over traditional lectin products, including rapid and cost-effective production through recombinant expression in Escherichia coli, high purity, consistent performance, and genetically enhanced binding properties that improve specificity and affinity. The scalable nature of their production also supports large-scale applications, making their technology valuable for various sectors within the life sciences.

Alliance Protein Laboratories, Inc. is a contract research and consulting firm based in San Diego, California, specializing in biophysical and biochemical analytical services. Founded in 1998, the company focuses on the characterization, aggregation, purification, and stabilization of proteins and peptides. Its offerings include a range of biophysical characterization services, contract purification services at the research scale, and consulting services. Alliance Protein Laboratories employs advanced techniques such as analytical ultracentrifugation and concentration-gradient multi-angle light scattering to support its clients in the analysis of proteins, nucleic acids, and other macromolecular assemblies. As of June 2018, the company operates as a subsidiary of KBI Biopharma Inc.

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing human enzyme therapeutics for patients with rare genetic and cancer-related diseases. The company's primary product candidate, pegzilarginase, is a recombinant human Arginase 1 enzyme currently undergoing Phase III trials to assess its safety and efficacy in treating Arginase 1 deficiency. Aeglea's preclinical pipeline includes several innovative candidates, such as ACN00177 for homocystinuria, AEB5100 which degrades plasma cystine and cysteine, AEB2109 targeting the degradation of methionine, and AEB3103. Founded in 2013, Aeglea BioTherapeutics aims to address unmet medical needs in the field of rare metabolic disorders through its specialized enzyme therapies.